DiaMedica Therapeutics Inc. (DMAC) financial statements (2022 and earlier)

Company profile

Business Address TWO CARLSON PARKWAY
MINNEAPOLIS, MN 55447
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:45,11227,5077,90016,823
Cash and cash equivalents4,7077,4093,88316,823
Short-term investments40,40520,0983,995 
Other undisclosed cash, cash equivalents, and short-term investments  22 
Receivables130340823780
Prepaid expense   369
Deposits current assets1131088 
Other undisclosed current assets846425 
Total current assets:45,43927,9218,83617,972
Noncurrent Assets
Operating lease, right-of-use asset42100153
Property, plant and equipment70746496
Deposits noncurrent assets   271
Total noncurrent assets:112174217367
TOTAL ASSETS:45,55128,0959,05318,339
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,4751,9631,2581,291
Accounts payable   483
Employee-related liabilities484483419417
Other undisclosed accounts payable and accrued liabilities9911,480839391
Debt46605
Other undisclosed current liabilities4559  
Total current liabilities:1,5242,0281,3181,296
Noncurrent Liabilities
Long-term debt and lease obligation35311818
Finance lease, liability3713
Capital lease obligations18
Operating lease, liability 46105
Other undisclosed noncurrent liabilities (46)  
Total noncurrent liabilities:35311818
Total liabilities:1,5272,0811,4361,314
Stockholders' equity
Stockholders' equity attributable to parent44,02426,0147,61717,025
Additional paid in capital126,57694,92564,23262,993
Accumulated other comprehensive income (loss)(51)(2)2 
Accumulated deficit(82,501)(68,909)(56,617)(45,968)
Total stockholders' equity:44,02426,0147,61717,025
TOTAL LIABILITIES AND EQUITY:45,55128,0959,05318,339

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues   500
Gross profit:   500
Operating expenses(13,646)(12,699)(11,593)(7,261)
Operating loss:(13,646)(12,699)(11,593)(6,761)
Nonoperating income824349751,107
Other nonoperating income (expense)82229119(68)
Loss from continuing operations before income taxes:(13,564)(12,265)(10,618)(5,654)
Income tax expense(28)(27)(31)(80)
Net loss available to common stockholders, diluted:(13,592)(12,292)(10,649)(5,734)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(13,592)(12,292)(10,649)(5,734)
Comprehensive loss:(13,592)(12,292)(10,649)(5,734)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(49)(4)2 
Comprehensive loss, net of tax, attributable to parent:(13,641)(12,296)(10,647)(5,734)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: